Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Gets FDA Expanded OK for Keytruda in Breast Cancer

07/27/2021 | 04:59am EDT

By Colin Kellaher

Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster cancer drug Keytruda in an aggressive type of breast cancer that has an increased risk for recurrence.

The Kenilworth, N.J., drugmaker said the approval covers Keytruda for the treatment of patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

Merck said Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is now approved for 30 indications in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

07-27-21 0659ET

All news about MERCK & CO., INC.
10:59aMERCK : Announces KEYTRUDA« (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
07:57aMERCK : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Canc..
MT
07:44aMERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
07:44aMERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
05:56aMerck Says Keytruda Liver Cancer Study Meets Objective
DJ
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
09/24AstraZeneca and Merck Announce Positive Results from the Phase 3 PROpel Trial
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,1x
Yield 2021 3,52%
Capitalization 186 B 186 B -
EV / Sales 2021 4,30x
EV / Sales 2022 3,89x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,61 $
Average target price 93,42 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.01%186 334
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037